Free Trial
NASDAQ:ENLV

Enlivex Therapeutics Q1 2023 Earnings Report

Enlivex Therapeutics logo
$0.96 +0.03 (+2.75%)
Closing price 05/30/2025 03:59 PM Eastern
Extended Trading
$0.94 -0.02 (-2.43%)
As of 05/30/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics EPS Results

Actual EPS
-$0.39
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Enlivex Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enlivex Therapeutics Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Thursday, June 15, 2023
Conference Call Time
6:00PM ET

Upcoming Earnings

Enlivex Therapeutics' Q1 2025 earnings is scheduled for Friday, June 13, 2025, with a conference call scheduled on Thursday, June 12, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Enlivex Therapeutics Earnings Headlines

Enlivex Therapeutics (NASDAQ:ENLV) Trading Down 4% - Time to Sell?
How Trade Wars Are Creating Fresh Opportunities for Investors
Tariffs and trade tensions are back in the headlines, and while many are focused on the risks, smart investors know there’s also opportunity. New supply chain shifts, pricing power adjustments, and sector revaluations are already underway—creating openings for those who act early. That’s why we’ve just released our latest research: 📈 “From Tariffs to Returns: How to Capitalize on Trade Disputes in Your Portfolio”
See More Enlivex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email.

About Enlivex Therapeutics

Enlivex Therapeutics (NASDAQ:ENLV), together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

View Enlivex Therapeutics Profile

More Earnings Resources from MarketBeat